Vitamin-based anti-metastatic therapy for Notch1-overexpressing Human cancers: Δ-Tocotrienol, a form of Vitamin-E, inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium, and prevents Notch1-driven metastasis via up regulation of its target gene, 24/May/2017, 7.28 am

Mechanical Stretch therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Mechanical Stretch therapy increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state via up-regulation of its target gene Lin28, 24/May/2017, 7.26 am
May 24, 2017
Natural product-derived therapy for metastatic prostate cancer: Agaricus blazei Murrill (AbM) mushroom extract inhibits the expression of CDC42, CDC42EP3, RAC1 and ARPC5, and GAS6, suppresses the expression of stem cell molecules CD44 and EZH2, promotes epithelial phenotype, suppresses tumorigenesis, migration, invasion, stem cell regeneration and metastasis via up regulation of its target gene, 24/May/2017, 7.29 am
May 24, 2017
Show all

Introduction: What they say:

A study from the Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Vascular Biology, CBTM, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany; Department of Medicine I and Clinical Chemistry, Heidelberg University Hospital, 69120 Heidelberg, Germany; and Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany shows that “Endothelial Notch1 Activity Facilitates Metastasis” This study was published in the 12 Feb 2017 issue of the journal “Cancer Cell” [the number 1 journal in Cancer Biology with an I.F of plus 23+] by Prof. Andreas Fischer, Elfriede Wieland, and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Vitamin-based anti-metastatic therapy for Notch1-overexpressing Human cancers: Δ-Tocotrienol, a form of Vitamin-E, inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium, and prevents Notch1-driven metastasis via up regulation of its target gene

Price 100

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer deaths are due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to activate his/her own immune system against tumors (Cancer immunotherapy); (ii) anticancer drugs that target cancer stem cells that aid in tumor relapse and resistance; (iii) a cheaper alternative to the existing expensive anticancer drugs; (iv) a side-effect-free natural product-based drug; (v) increase the therapeutic index of anti-cancer drugs; and (vi) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


What we infer from what they say:

Prof. Andreas Fischer’s research team has recently shown that activated Notch1 receptors (N1ICD): (1) are frequently overexpressed in endothelial cells of human carcinomas and melanoma; (2) promote neutrophil infiltration; (3) promote tumor cell adhesion to the endothelium; (4) induce intravasation; (5) promote lung colonization; (6) promote postsurgical metastasis; (7) inhibit the expression of cell adhesion molecule VCAM1; and (8) inhibit invasion, migration, and metastasis. Further, they have shown that inhibition of Notch1 or VCAM1 expression stalls peritoneal neutrophil infiltration and metastatic progression of cancers.


From research findings to therapeutic opportunity :

This study suggests a vitamin-based therapy for metastatic tumors. Δ-Tocotrienol has been shown to inhibit proliferation of a number of cancer cells (fig. 1). However, the detailed mechanistic insights is yet to emerge.

Δ-Tocotrienol, by increasing the expression of its target genes, it may decrease the expression of Notch1 and its downstream signalling (fig. 1). Thereby, it may: (i) inhibit the expression of adhesion molecule VCAM1; (ii) suppress neutrophil infiltration; (iii) suppress tumor cell adhesion to the endothelium; and (iv) inhibit invasion, migration and metastasis.

Figure 1. Delta-Tocotrienol functions as an antimetastatic agent. Mechanistic insights into how Delta-Tocotrienol suppresses the expression of Notch-1 and VCAM to inhibit metastatic progression.

Thus, pharmacological formulations encompassing Δ-Tocotrienol or its analogues, either alone or in combination with other known anticancer drugs,” (fig.1) may be used to inhibit metastatic progression of cancers, including metastatic melanoma.

[easy_payment currency=”USD”]


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Amount: $100#

Undisclosed mechanistic information: How does Δ-Tocotrienol decrease the expression of Notch-1 and VCAM to promote metastatic tumor regression?

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

#Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Vitamin-based anti-metastatic therapy for Notch1-overexpressing Human cancers: Δ-Tocotrienol, a form of Vitamin-E, inhibits the expression of Notch1, and adhesion molecule VCAM1, suppresses neutrophil infiltration and tumor cell adhesion to endothelium, and prevents Notch1-driven metastasis via up regulation of its target gene, 24/May/2017,  7.28 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, Kindly drop us a line at admin@genomediscovery.org

Comments are closed.